Stock TBIO TELESIS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Telesis Bio, Inc.

Equities

TBIO

US1920031010

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.3214 USD +0.03% Intraday chart for Telesis Bio, Inc. -2.90% -19.45%
Apr. 18 Telesis Bio, Inc. Announces Appointment of Eric Esser to the Board of Directors CI
Apr. 18 Telesis Bio Inc. Announces Strategic Focus on Game-Changing Gibson Sola Enzymatic DNA Synthesis Platform and BioXp mRNA Solutions CI

Evolution of the average Target Price on Telesis Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

97fb16840fb.qmr0kFGB-Y0N3u02HyR6ilo0va1nvnzU3SOigie0j24.wD7E8Rm5iel7trV-LRBXvg5E7NgIhx-4jXbPw1Hz91jTXqXjCOieuFSPhg~2bafef2f828a75d2d80bda5636e88fb8

Analyst Recommendations on Telesis Bio, Inc.

KeyBanc Downgrades Telesis Bio to Sector Weight From Overweight, Cites 'Limited Top-Line Visibility' Amid 'Tepid Biopharma Spending Environment' MT
KeyBanc Capital Markets Adjusts Price Target on Codex DNA to $5 From $8, Maintains Overweight Rating MT
KeyBanc Adjusts Codex DNA's Price Target to $8 From $30, Keeps Overweight Rating MT
CODEX DNA : Cowen Starts Codex DNA at Outperform MT
CODEX DNA : Jefferies Starts Codex DNA at Buy With $23 Price Target MT
CODEX DNA : KeyBanc Starts Codex DNA at Overweight With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3214
Average target price
-

Consensus detail

Consensus revision (last 18 months)

Analysts covering Telesis Bio, Inc.

KeyBanc Capital Markets
Cowen
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TBIO Stock
  4. Consensus Telesis Bio, Inc.